TLPPF - Telix Pharmaceuticals Limited (TLPPF) Q4 2023 Earnings Call Transcript
2024-02-22 23:36:10 ET
Telix Pharmaceuticals Limited (TLPPF)
Q4 2023 Earnings Conference Call
February 22, 2024 17:00 ET
Company Participants
Kyahn Williamson - Senior Vice President of Investor Relations & Corporate Communications
Christian Behrenbruch - Managing Director & Group Chief Executive Officer
Darren Smith - Group Chief Financial Officer
David Cade - Group Chief Medical Officer
Conference Call Participants
David Stanton - Jefferies
Laura Sutcliffe - UBS
John Hester - Bell Potter
Presentation
Operator
Thank you for standing by, and welcome to the Telix Pharmaceuticals Limited FY2023 Results Call. [Operator Instructions] I would now like to hand the conference over to Mr. Kyahn Williamson, Senior Vice President, Investor Relations and Corporate Communication. Please go ahead.
Kyahn Williamson
Thank you. Thank you, everybody, for joining our call this morning. You'll have seen that we have launched our annual report and full-year results on the ASX after market closed yesterday. Joining me today on the call is Chris Behrenbruch, Managing Director and Group Chief Executive Officer; Darren Smith, our Group Chief Financial Officer; and Dr. David Cade, our Group Chief Medical Officer.
If we just turn slide 4, please? Just a few introductory remarks. I mean, it's been a very exciting news to hear at Telix and a lot of hard work, which has led to a lot of achievements. It's been our first full year of commercial sales with reimbursement of Illuccix in the US, and that's delivered 214% growth in revenues to achieve a total revenue of just over $0.5 billion. It really shows the strength of demand for Illuccix, but has also demonstrated our ability to build a highly effective and profitable commercial business.
The operational highlights we've achieved this year are really driving towards our next phase of value creation. We are preparing to launch two new additional diagnostic imaging agents subject to regulatory approval by the end of this year. And that allows us to layer in new revenue streams. And also particularly the case of Zircaix, further strengthen our offering to the urology field as a perfect follow-on product to Illuccix....
Telix Pharmaceuticals Limited (TLPPF) Q4 2023 Earnings Call Transcript